QC
NBIX icon

Quent Capital’s Neurocrine Biosciences NBIX Stock Holding History

Quent Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9K Sell
130
-58
-31% -$8.61K ﹤0.01% 1034
2026
Q1 		$24.8K Sell
188
-57
-23% -$7.56K ﹤0.01% 920
2025
Q4 		$34.7K Buy
245
+14
+6% +$2.03K ﹤0.01% 847
2025
Q3 		$32.4K Buy
+231
New +$31.3K ﹤0.01% 731
2025
Q2 		– Sell
-74
Closed -$8.18K – 902
2025
Q1 		$8.18K Hold
74
– – ﹤0.01% 939
2024
Q4 		$10.1K Sell
74
-84
-53% -$10.4K ﹤0.01% 933
2024
Q3 		$18.2K Hold
158
– – ﹤0.01% 902
2024
Q2 		$21.8K Hold
158
– – ﹤0.01% 821
2024
Q1 		$21.8K Buy
158
+117
+285% +$16K ﹤0.01% 857
2023
Q4 		$5.4K Buy
41
+32
+356% +$3.68K ﹤0.01% 1059
2023
Q3 		$1.01K Hold
9
– – ﹤0.01% 1240
2023
Q2 		$849 Hold
9
– – ﹤0.01% 1251
2023
Q1 		$911 Hold
9
– – ﹤0.01% 1246
2022
Q4 		$1.07K Hold
9
– – ﹤0.01% 1222
2022
Q3 		$1K Hold
9
– – ﹤0.01% 1166
2022
Q2 		$1K Sell
9
-100
-92% -$9.23K ﹤0.01% 1118
2022
Q1 		$10K Buy
109
+100
+1,111% +$8.47K ﹤0.01% 910
2021
Q4 		$1K Buy
+9
New +$828 ﹤0.01% 1046

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quent Capital's NBIX Position: Q2 2026 in Review

Quent Capital reduced its Neurocrine Biosciences (NBIX) stake by 31% in Q2 2026, selling an estimated $8.61K and leaving 130 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1034.

Quent Capital first reported a position in NBIX in Q4 2021 and has held it in 18 quarters since. The position peaked at $34.7K in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Quent Capital held 130 shares of Neurocrine Biosciences worth $21.9K as of Q2 2026.
  • Quent Capital sold 58 Neurocrine Biosciences shares in Q2 2026, an estimated $8.61K.
  • Neurocrine Biosciences made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1034 holding.
  • Quent Capital first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 18 quarters since.
  • Quent Capital's Neurocrine Biosciences position peaked at $34.7K in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.